Skip to main content

Table 2 Adverse events of patients in 12 mg/day group (the 2/1 schedule)

From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Adverse events

Grade 1/2

Grade 3

First 2 cycles

All cycles

First 2 cycles

All cycles

No. of patients

%

No. of patients

%

No. of patients

%

No. of patients

%

Occurred at least one time

21

100

21

100

2

10

6

29

Hand-foot skin reaction

4

19

10

48

0

0

1

5

Rash

4

19

6

29

0

0

0

0

Hypertension

5

24

5

24

0

0

2

10

Proteinuria

5

24

14

67

0

0

0

0

Triglyceride elevation

6

29

11

52

1

5

2

10

Total cholesterol elevation

6

29

13

62

0

0

0

0

Hypothyroidism

8

38

12

57

0

0

0

0

Hyperthyroidism

2

10

2

10

0

0

0

0

ALT elevation

6

29

10

48

0

0

0

0

AST elevation

4

19

9

43

0

0

0

0

Creatinine elevation

1

5

2

10

0

0

0

0

Total bilirubin elevation

5

24

8

38

0

0

0

0

Lipase elevation

1

5

5

24

1

5

1

5

Serum amylase

4

19

9

43

0

0

0

0

Myocardial enzymes abnormal

2

10

3

14

0

0

0

0

Leukopenia

3

14

6

29

0

0

0

0

Neutropenia

0

0

2

10

0

0

0

0

Thrombocytopenia

0

0

2

10

0

0

0

0

Hemorrhage

0

0

1

5

0

0

0

0

Urine occult blood

5

24

8

38

0

0

0

0

Fatigue

5

24

7

33

0

0

0

0

Diarrhea

6

29

7

33

0

0

0

0

Hoarseness

3

14

5

24

0

0

0

0

Nausea

3

14

3

14

0

0

0

0

Inappetence

1

5

2

10

0

0

0

0

Toothache

1

5

4

19

0

0

0

0

Pharyngalgia

1

5

4

19

0

0

0

0

Premature beat

0

0

1

5

0

0

0

0

  1. ALT alanine aminotransferase, AST aspartate transaminase